Roshe and Atea Pharmaceuticals will work together to develop the antiviral oral drug AT-527, which may be effective for outpatient treatment of COVID-19 in the early stages of the disease. AT-527 is undergoing a second phase of testing and, if successful, Atea will distribute the drug throughout the U.S. and Roshe will be responsible for deliveries outside the states.